PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

(2013) Todd M. Pitts et al.   Frontiers in Pharmacology

p21-Activated kinase 4 promotes prostate cancer progression through CREB

(2012) M-H Park et al.   ONCOGENE

Notice of Retraction

(2011)   CARCINOGENESIS

Silymarin Targets β-Catenin Signaling in Blocking Migration/Invasion of Human Melanoma Cells

(2011) Mudit Vaid et al.   PLoS One

The emerging importance of group II PAKs

(2010) Claire M. Wells et al.   BIOCHEMICAL JOURNAL

p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients

(2010) M. K. Y. Siu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

(2010) B. W. Murray et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting group II PAKs in cancer and metastasis

(2009) Jeyanthy Eswaran et al.   CANCER AND METASTASIS REVIEWS

Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human breast cancer cell line

(2009) Supachai Yodkeeree et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Tumor microenvironment and angiogenesis

(2008) Pia Nyberg   Frontiers in Bioscience-Landmark

UnPAKing the class differences among p21-activated kinases

(2008) Jeyanthy Eswaran et al.   TRENDS IN BIOCHEMICAL SCIENCES